Drug intelligence / Profile preview

PEG-ADA2-E182T

Development stage: Discontinued
Lead developer: Halozyme
Modality: Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Subcutaneous

Overview

PEG-ADA2-E182T is a pegylated, engineered recombinant human adenosine deaminase 2 (ADA2) variant developed by Halozyme Therapeutics. It was specifically designed with an E182T mutation to eliminate enzymatic activity, serving as a negative control in preclinical studies investigating the role of adenosine depletion in the tumor microenvironment. While active PEG-ADA2 variants (such as PEG-ADA2-K374D) demonstrated significant tumor growth inhibition by reducing immunosuppressive adenosine levels, PEG-ADA2-E182T showed no anti-tumor activity, confirming that the therapeutic effect of this class of immunotherapies is dependent on ADA2 enzymatic function.

Beyond the preview

Go deeper on PEG-ADA2-E182T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEG-ADA2-E182T.

Explore the full profile